After Glenmark's Fabiflu, a second favipiravir-based formulation has received approval from India's drug regulator, as reported in Business Standard.
Brinton Pharmaceuticals claimed that it has obtained the nod from the Drug Controller General of India (DCGI) to market its brand Faviton.
According to the news source, Faviton would be priced at Rs 59 per tablet as against Rs 75 per tablet for FabiFlu.
In India, favipiravir was first approved by the regulatory authorities in June under emergency use authorisation to treat COVID-19 patients.
Rahul Kumar Darda, managing director at Brinton Pharma said "our strategic intent will be to improve access through our strong distribution network that will help make Faviton available across all COVID-19 treatment centers."
To read more NewsPoints articles, click here.